New hope for stomach and bowel cancers: experimental drug Rina-S enters Mid-Stage trial
NCT ID NCT07539311
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial is testing a new drug called Rina-S (rinatabart sesutecan) in about 160 people with advanced gastrointestinal cancers that have spread or cannot be removed. The drug is given alone through an IV, and everyone receives it—no placebo. The study will check if the drug shrinks tumors and how long that effect lasts, while also monitoring side effects. Participants may continue treatment as long as their cancer does not worsen and side effects are manageable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rina-S (rinatabart sesutecan)
What this could lead to
If it works, this could point toward a new treatment option for advanced gastrointestinal cancers that have not responded to other therapies.
What could go wrong
This is an early Phase 2 trial with a small number of participants, so results may not confirm effectiveness. Side effects are possible, and the drug may not work for all cancer types studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL CANCERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
START San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States